Senti Biosciences Holdings, Inc. SEC filings SNTI
Senti Biosciences Holdings, Inc. has 367 filings in SEC EDGAR's recent list, going back to Apr 2, 2021. Its latest annual report, Form ARS, was filed on Jul 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 24, 2026 | — |
| PRER14A | Filing | Sep 24, 2026 | — |
| PRER14A | Filing | Sep 4, 2026 | — |
| D | Filing | Jun 4, 2026 | — |
| 15-12G | Deregistration | May 8, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| 8-K12B | Filing | Apr 24, 2026 | Apr 24, 2026 |
| EFFECT | Filing | Mar 31, 2025 | — |
| EFFECT | Filing | Mar 31, 2025 | — |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| D | Filing | Dec 19, 2024 | — |
| EFFECT | Filing | Nov 3, 2023 | — |
| EFFECT | Filing | Nov 3, 2023 | — |
| EFFECT | Filing | Sep 29, 2022 | — |
| CORRESP | Letter to the SEC | Sep 27, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 15, 2022 | — |
| EFFECT | Filing | Aug 8, 2022 | — |
| CORRESP | Letter to the SEC | Aug 4, 2022 | — |
| CORRESP | Letter to the SEC | Jul 29, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2022 | — |
| 425 | Filing | Jun 7, 2022 | — |
| 425 | Filing | May 25, 2022 | — |
| 425 | Filing | May 24, 2022 | — |
| SEC STAFF LETTER | Filing | May 16, 2022 | — |
| EFFECT | Filing | May 13, 2022 | — |
| CORRESP | Letter to the SEC | May 12, 2022 | — |
| CORRESP | Letter to the SEC | May 12, 2022 | — |
| 425 | Filing | May 10, 2022 | — |
| SEC STAFF LETTER | Filing | May 4, 2022 | — |
| CORRESP | Letter to the SEC | Apr 22, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 19, 2022 | — |
| CORRESP | Letter to the SEC | Apr 1, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 14, 2022 | — |
| 425 | Filing | Feb 15, 2022 | — |
| 425 | Filing | Dec 20, 2021 | — |
| EFFECT | Filing | May 25, 2021 | — |
| CERT | Filing | May 25, 2021 | — |
| 8-A12B | Form 8-a12b | May 25, 2021 | — |
| CORRESP | Letter to the SEC | May 24, 2021 | — |
| CORRESP | Letter to the SEC | May 24, 2021 | — |
| CORRESP | Letter to the SEC | May 20, 2021 | — |
| UPLOAD | Letter from the SEC | May 19, 2021 | — |
| CORRESP | Letter to the SEC | May 7, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2021 | — |
| DRS | Filing | Apr 2, 2021 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SNTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1854270
- Former names
- Senti Biosciences, Inc. (until May 8, 2026); Senti Biosciences, Inc.\ (until Jun 28, 2022); Dynamics Special Purpose Corp. (until Jun 13, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.